Information Provided By: 
Fly News Breaks for June 27, 2018
CLVS, TSRO
Jun 27, 2018 | 08:41 EDT
Barclays transferred coverage of Tesaro (TSRO) to Gena Wang, who set an Overweight rating on the stock with a $60 price target. Barclays previously had an Equal Weight rating on the name. Both Tesaro and Clovis (CLVS) have pulled back after initial enthusiasm on the PARP inhibitors as a drug class in oncology, but Wang still sees great potential for PARPi to penetrate broader cancer indications and believes the collective global market opportunity is large enough for multiple players.
News For TSRO;CLVS From the Last 2 Days
There are no results for your query TSRO;CLVS
